BTIG downgraded Alector (ALEC) to Neutral from Buy without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm says the study outcome makes it “leery” of the ongoing PROGRESS-AD trial where a similar approach is being tested to see if increased levels of extracellular protein progranulin will help patients with Alzheimer’s disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector downgraded to Market Perform from Outperform at William Blair
- Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
- Alector downgraded to Neutral from Outperform at Mizuho
- Alector downgraded to Hold from Buy at TD Cowen
- Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings